Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

INTRODUCTION: The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open Diabetes Res Care
Hlavní autoři: Buse, John B, Bode, Bruce W, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Nielsen, Morten A, Pieber, Thomas R
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Emerging Technologies, Pharmacology and Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7737050/
https://ncbi.nlm.nih.gov/pubmed/33318068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2020-001649
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky